360 related articles for article (PubMed ID: 22863529)
1. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
4. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
Lee J; Han SY; Jung H; Yang J; Choi JW; Chae CH; Park CH; Choi SU; Lee K; Ha JD; Lee CO; Ryu JW; Kim HR; Koh JS; Cho SY
Bioorg Med Chem Lett; 2012 Jun; 22(12):4044-8. PubMed ID: 22579487
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Liu L; Norman MH; Lee M; Xi N; Siegmund A; Boezio AA; Booker S; Choquette D; D'Angelo ND; Germain J; Yang K; Yang Y; Zhang Y; Bellon SF; Whittington DA; Harmange JC; Dominguez C; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1868-97. PubMed ID: 22320327
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
[TBL] [Abstract][Full Text] [Related]
10. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
12. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel type II c-Met inhibitors based on BMS-777607.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Eur J Med Chem; 2014 Jun; 80():254-66. PubMed ID: 24792774
[TBL] [Abstract][Full Text] [Related]
14. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
